Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Sglt2i Use In Non-Diabetics, Sarah Nadeem, Masooma Rana, Kaleem Ahmed, Sanjay Kalra
Sglt2i Use In Non-Diabetics, Sarah Nadeem, Masooma Rana, Kaleem Ahmed, Sanjay Kalra
Section of Diabetes, Endocrinology and Metabolism
No abstract provided.
The Outcomes Of Dapagliflozin Use In Real-Life Clinical Settings In Endocrinology Clinics Of Islamabad, Pakistan, Matiullah Kamin, Osama Ishtiaq, Kashif Raashid, Muhammad Umar Wahab, Sajjad A. Khan, Umar Raja
The Outcomes Of Dapagliflozin Use In Real-Life Clinical Settings In Endocrinology Clinics Of Islamabad, Pakistan, Matiullah Kamin, Osama Ishtiaq, Kashif Raashid, Muhammad Umar Wahab, Sajjad A. Khan, Umar Raja
Section of Diabetes, Endocrinology and Metabolism
Introduction: Dapagliflozin is a member of a novel class of drugs (sodium-glucose cotransporter-2 inhibitors) used to treat type 2 diabetes mellitus and licensed in Pakistan in 2017. This retrospective observational study evaluated the effects of dapagliflozin on glycated hemoglobin (HbA1c) concentrations in patients treated at endocrinology clinics in Islamabad, Pakistan. The secondary objectives included assessing the effects of dapagliflozin on weight reduction and blood pressure control and to determining its safety.
Methodology: Patients with type 2 diabetes who were treated with dapagliflozin were identified by screening the electronic medical records at tertiary care hospitals in Islamabad. Data were collected at …